Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections
- 26 June 2015
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (12) , 3850-3861
Abstract
The aim of this work was to develop clarithromycin microparticles (CLARI-MP) and evaluate their aerodynamic behavior, safety in bronchial cells and anti-bacterial efficacy. Microparticles containing clarithromycin were prepared as dry powder carrier for inhalation, using leucine and chitosan. CLARI-MP were deposited on Calu-3 grown at air-interface condition, using the pharmaceutical aerosol deposition device on cell cultures (PADDOCC). Deposition efficacy, transport across the cells and cytotoxicity were determined. Anti-antibacterial effect was evaluated against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus. Microparticles were of spherical shape, smooth surface and size of about 765 nm. Aerosolization performance showed a fine particle fraction (FPF) of 73.3%, and a mass median aerodynamic diameter (MMAD) of 1.8 μm. Deposition on Calu-3 cells using the PADDOCC showed that 8.7 μg/cm2 of deposited powder were transported to the basolateral compartment after 24 h. The safety of this formulation is supported by the integrity of the cellular epithelial barrier and absence of toxicity, and the antimicrobial activity demonstrated for Gram positive and Gram negative bacteria. The appropriate aerodynamic properties and the excellent deposition on Calu-3 cells indicate that clarithromycin microparticles are suitable for administration via pulmonary route and are efficient to inhibit bacteria proliferation.Keywords
This publication has 48 references indexed in Scilit:
- New insights in the production of aerosol antibiotics. Evaluation of the optimal aerosol production system for ampicillin-sulbactam, meropenem, ceftazidime, cefepime and piperacillin-tazobactamInternational Journal of Pharmaceutics, 2013
- Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosolsInternational Journal of Pharmaceutics, 2013
- Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetesInternational Journal of Nanomedicine, 2013
- New Co-Spray-Dried Tobramycin Nanoparticles-Clarithromycin Inhaled Powder Systems for Lung Infection Therapy in Cystic Fibrosis PatientsJournal of Pharmaceutical Sciences, 2013
- Fosfomycin/Tobramycin for Inhalation in Patients with Cystic Fibrosis with Pseudomonas Airway InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Chitosan–interferon-β gene complex powder for inhalation treatment of lung metastasis in miceJournal of Controlled Release, 2011
- Progress in developing spray-drying methods for the production of controlled morphology particles: From the nanometer to submicrometer size rangesAdvanced Powder Technology, 2011
- Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactionsJournal of Pharmacy and Bioallied Sciences, 2011
- A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulationsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Evaluation of the Nano Spray Dryer B-90 for pharmaceutical applicationsPharmaceutical Development and Technology, 2010